Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging
Open accessThe DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
Synapses are implicated in many neuropsychiatric illnesses. Here, we provide an overview of in vivo techniques to index synaptic markers in patients. Several positron emission tomography (PET) tracers for synaptic vesicle glycoprotein 2 A (SV2A) show good reliability and selectivity. We review over 50 clinical studies including over 1700 participants, and compare findings in healthy ageing and across disorders, including addiction, schizophrenia, depression, posttraumatic stress disorder, and neurodegenerative disorders, including tauopathies, Huntington’s disease and α-synucleinopathies. These show lower SV2A measures in cortical brain regions across most of these disorders relative to healthy volunteers, with the most well-replicated findings in tauopathies, whilst changes in Huntington’s chorea, Parkinson’s disease, corticobasal degeneration and progressive supranuclear palsy are predominantly subcortical. SV2A PET measures are correlated with functional connectivity across brain networks, and a number of other measures of brain function, including glucose metabolism. However, the majority of studies found no relationship between grey matter volume measured with magnetic resonance imaging and SV2A PET measures. Cognitive dysfunction, in domains including working memory and executive function, show replicated inverse relationships with SV2A measures across diagnoses, and initial findings also suggest transdiagnostic relationships with mood and anxiety symptoms. This suggests that synaptic abnormalities could be a common pathophysiological substrate underlying cognitive and, potentially, affective symptoms. We consider limitations of evidence and future directions; highlighting the need to develop postsynaptic imaging markers and for longitudinal studies to test causal mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Colocalisation of SV2A and synaptophysin in the baboon brain. a High-power confocal microscopy of 4’,6-diamidino-2-phenylindole (DAPI), synaptophysin (SYN), and synaptic vesicle glycoprotein 2A (SV2A) in the grey matter of the baboon brain. Labelling for SYN and SV2A is evident as punctate staining in the neuropil, particularly surrounding neuronal cell bodies and proximal dendrites (yellow arrow), but absent in neuronal cell bodies (white arrows). Nuclei are indicated by the DAPI stain in blue. b Correlation between in vitro SV2A and in vitro SYN density in grey matter regions determined using Western blot analyses. Data are nine brain regions. Figure and legend reproduced from Finnema et al. with permission (2016) [47]. GM grey matter, OD optical density.](https://figures.cochat.ai/paper-figures/2c2f620148394437ad243a03bed4455e/synaptic-changes-in-psychiatric-and-neurological-disorders-state-of-the-art-of-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Depression cohorts show lower binding with evidence that pharmacologic challenges can probe synaptogenesis in vivo [212].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across disorders, SV2A PET consistently reveals synaptic loss [210,211,212].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [212]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NODDI: Practical in vivo neurite orientation dispersion and density imaging of the human brain
Zhang, H., Schneider, T., Wheeler-Kingshott, C. A., & Alexander, D. C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.072 · Cited by 3,288 · cited 1×
“Neurite orientation dispersion and density imaging (NODDI) can provide measures of both the density and angular variation of neurites, with the signal dependent on factors such as dendritic arborisation [107].”
BackgroundThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757 · cited 1×
“While a general pathophysiology underlying different addictions has been proposed [73], evidence from these three studies does not suggest there is a common pattern of synaptic terminal loss in speci fi c brain regions based on the limited literature to date.”
BackgroundSynaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323 · cited 1×
“The binding of neurotransmitter can produce diverse effects, including excitation, inhibition and induction of synaptic plasticity [12].”
BackgroundSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208 · cited 1×
“These studies are therefore consistent with the theory suggesting that tau accumulation precedes and underlies synaptic pathology in tauopathies [112 – 115].”
ResultSimplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“…major advantages of BP ND include its versatility, as it can be calculated both using an AIF from V T estimates, providing an outcome measure equalling DVR-1 [7], or using a simpli fi ed reference tissue model (SRTM) which is used to estimate the input function from the reference without ABS [161].”
MethodConsensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955 · cited 2×
“BP ND : BP ND is calculated using the ratio of speci fi c to nondisplaceable volume of distribution [21].”
BackgroundMethodSynaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747 · cited 2×
“However, it is important to note FDG changes could also re fl ect degeneration of the axons, glia and cell bodies, which make up the remaining half of brain ATP use [117].”
BackgroundChemical Nature of Synaptic Transmission in Vertebrates
Krnjević, K. (1974) · Physiological Reviews · doi:10.1152/physrev.1974.54.2.418 · Cited by 1,610 · cited 10×
“The two studies in patients with chronic illness, using V T [55] and BP ND , derived from V T estimates [58] respectively, both showed lower [ 11 C]UCB-J uptake in the cortex and hippocampus, with similar effect sizes.”
BackgroundMethodResultInfluentialThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 2×
“One of the fi rst produced was [ 11 C]LEV, based on the SV2A modulator levetiracetam [22].”
BackgroundSynaptotagmin: a Calcium Sensor on the Synaptic Vesicle Surface
Brose, N., Petrenko, A. G., Südhof, T. C., & Jahn, R. (1992) · Science · doi:10.1126/science.1589771 · Cited by 979 · cited 1×
“…[14], responding to calcium in fl ux into the presynaptic terminal to initiate exocytosis, mediated by synaptotagmin, a calcium sensor [15], and for fusing with the synaptic terminal membrane, mediated by the soluble N -ethylamide-sensitive factor attachment protein receptor (SNARE)…”
BackgroundWhite Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Davis, K. L., Stewart, D. G., Friedman, J. I., Buchsbaum, M., Harvey, P. D., Hof, P. R., Buxbaum, J., & Haroutunian, V. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.5.443 · Cited by 793
White matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes
Nasrabady, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0515-3 · Cited by 723
Specificity and regulation of a synaptic vesicle docking complex
Pevsner, J., Hsu, S.-C., Braun, J. E. A., Calakos, N., Ting, A. E., Bennett, M. K., & Scheller, R. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90352-2 · Cited by 592 · cited 1×
“The SNARE complex comprises a membrane component and the vesicle protein synaptobrevin [16].”
BackgroundImaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 2×
“…a baboon study investigating both synaptophysin immunolabelling and [ 11 C]UCB-J V T showed a very close correlation between V T and synaptophysin immuno fl uorescence [47], providing cross-validation between the PET measure and one of the most widely used ex vivo synaptic markers (Fig.”
BackgroundUnderstanding complexity in the human brain
Bassett, D. S., & Gazzaniga, M. S. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.03.006 · Cited by 572 · cited 1×
“Most complex brain functions rely on synapses [1].”
BackgroundDejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., Jiang, Z., Gandham, V., Friedman, B. A., Ngu, H., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.014 · Cited by 517
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484 · cited 4×
“…in later-life depression versus controls, while in a study including people with either MDD or posttraumatic stress disorder (PTSD), Holmes et al. [64] found lower [ 11 C]UCB-J V T in the dorsolateral prefrontal cortex (dlPFC), hippocampus and anterior cingulate cortex (ACC) in patients with more…”
BackgroundMethodResultInfluentialParkes, L. M., Rashid, W., Chard, D. T., & Tofts, P. S. (2004) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20023 · Cited by 449
The hippocampal–prefrontal pathway: The weak link in psychiatric disorders?
Godsil, B. P., Kiss, J. P., Spedding, M., & Jay, T. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.018 · Cited by 434 · cited 2×
“…in a variety of affective, intellectual and motivational processes which are central to illnesses with behavioural and cognitive symptoms [120]; and is consistent with evidence that hippocampal-prefrontal pathways consistently show dysfunction in electrophysiological and neuroimaging…”
ResultChen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431 · cited 3×
“Studies also report changes in the amygdala [76, 77], the parahippocampus [76, 78], and the thalamus [74, 78, 81] (Table 5).”
BackgroundIn vivo magnetic resonance spectroscopy of GABA: A methodological review
Puts, N. A. J., & Edden, R. A. E. (2012) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2011.06.001 · Cited by 393 · cited 1×
“However, this interpretation remains speculative [109].”
Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386 · cited 1×
“Unsurprisingly, therefore, synaptic alterations are implicated in many neurological and psychiatric disorders [2, 3].”
BackgroundNeuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau)
Dickson, D. W., Kouri, N., Murray, M. E., & Josephs, K. A. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9589-0 · Cited by 380
MATTSON, M. P., PEDERSEN, W. A., DUAN, W., CULMSEE, C., & CAMANDOLA, S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07824.x · Cited by 348 · cited 1×
“However, interestingly, there is evidence for a greater spatial extent of FDG than SV2A PET alterations, indicating FDG may capture metabolic signs of synaptic impairment before overt loss of synaptic terminals [119].”
BackgroundSelective Blockade of N‐Type Calcium Channels by Levetiracetam
Lukyanetz, E. A., Shkryl, V. M., & Kostyuk, P. G. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.24501.x · Cited by 338 · cited 1×
“While it shows negligible binding at the SV2 isoforms SV2B and SV2C [22], it has also been shown to bind to N-type voltage gated calcium channels [40] and AMPA receptors [41], although its af fi nity at these sites has not been reported.”
BackgroundNumber of parallel fiber synapses on an individual Purkinje cell in the cerebellum of the rat
Napper, R. M. A., & Harvey, R. J. (1988) · Journal of Comparative Neurology · doi:10.1002/cne.902740204 · Cited by 325
Hippocampal-Prefrontal Interactions in Cognition, Behavior and Psychiatric Disease
Sigurdsson, T., & Duvarci, S. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00190 · Cited by 309 · cited 1×
“…motivational processes which are central to illnesses with behavioural and cognitive symptoms [120]; and is consistent with evidence that hippocampal-prefrontal pathways consistently show dysfunction in electrophysiological and neuroimaging studies across multiple psychiatric illnesses [120, 121].”
ResultDuric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304 · cited 1×
“However, synaptic changes may occur after death [5], and cause of death may affect synapses [6].”
BackgroundComparative evaluation of synaptophysin-based methods for quantification of synapses
Calhoun, M. E., Jucker, M., Martin, L. J., Thinakaran, G., Price, D. L., & Mouton, P. R. (1996) · Journal of Neurocytology · doi:10.1007/bf02284844 · Cited by 302 · cited 1×
“Synaptic markers have historically been measured postmortem, often utilising immuno fl uorescence to study the density of synaptic vesicle proteins [4].”
BackgroundLee, B. R., Ma, Y.-Y., Huang, Y. H., Wang, X., Otaka, M., Ishikawa, M., Neumann, P. A., Graziane, N. M., Brown, T. E., Suska, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3533 · Cited by 296 · cited 1×
“The authors suggest it is related to the formation of silent synapses in the brain during cocaine use, which has been observed in mice [71, 72].”
BackgroundNabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168179 · Cited by 296 · cited 3×
“Of the UCB tracers, [ 11 C]UCB-J has higher af fi nity for SV2A [27] (Table 1) and higher speci fi c signal than [ 18 F]UCB-H [27].”
BackgroundIn Vivo Cocaine Experience Generates Silent Synapses
Huang, Y. H., Lin, Y., Mu, P., Lee, B. R., Brown, T. E., Wayman, G., Marie, H., Liu, W., Yan, Z., Sorg, B. A., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.007 · Cited by 289 · cited 1×
“The authors suggest it is related to the formation of silent synapses in the brain during cocaine use, which has been observed in mice [71, 72].”
BackgroundIn vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET
Mecca, A. P., Chen, M., O'Dell, R. S., Naganawa, M., Toyonaga, T., Godek, T. A., Harris, J. E., Bartlett, H. H., Zhao, W., Nabulsi, N. B., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12097 · Cited by 288 · cited 5×
“Findings consistent with lower SV2A levels in entorhinal cortex [74 – 77] and the hippocampus [28, 74, 76 – 83] (Table 5, Supplementary Table 4) were most widely reported.”
BackgroundMethodResultInfluentialWang, R., Liu, M., Cheng, X., Wu, Y., Hildebrandt, A., & Zhou, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022288118 · Cited by 280 · cited 1×
“…in cortical regions are related to functional connectivity measures across the brain highlights that SV2A alterations in speci fi c cortical regions could have widespread effects, and potentially lead to mood [126] and anxiety [127] symptoms, negative symptoms [128], and cognitive impairments [129].”
Backgroundde Wilde, M. C., Overk, C. R., Sijben, J. W., & Masliah, E. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.12.005 · Cited by 278
Gillard, M., Fuks, B., Leclercq, K., & Matagne, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.04.064 · Cited by 253 · cited 1×
“Brivaracetam, another SV2A modulator shows higher af fi nity for the protein (K i = 225 nM) than levetiracetam [42] and strong evidence of selectivity, with no speci fi c binding observed in SV2A knockout mice [42].”
BackgroundReward functions of the basal ganglia
Schultz, W. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1510-0 · Cited by 248 · cited 1×
“…in particular tauopa-thies, HD, PD dementia and LBD. Subcortical changes were seen in all illnesses with motor symptoms, such as spinocerebellar ataxia, HD, PSP and PD, but also in schizophrenia and MDD, which could re fl ect the role of these regions in salience and affective states [122].”
BackgroundOnwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243 · cited 7×
“The two studies in patients with chronic illness, using V T [55] and BP ND , derived from V T estimates [58] respectively, both showed lower [ 11 C]UCB-J uptake in the cortex and hippocampus, with similar effect sizes.”
BackgroundMethodInfluentialSelf-citationA role for white matter abnormalities in the pathophysiology of bipolar disorder
Mahon, K., Burdick, K. E., & Szeszko, P. R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.10.012 · Cited by 228
Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218 · cited 1×
“6 [ 154 ] [ 18 F ] U C B -”
Hanganu, A., Bedetti, C., Degroot, C., Mejia-Constain, B., Lafontaine, A.-L., Soland, V., Chouinard, S., Bruneau, M.-A., Mellah, S., Belleville, S., et al. (2014) · Brain · doi:10.1093/brain/awu036 · Cited by 213 · cited 1×
“Nevertheless, synaptic alterations may underlie cognitive impairments in PD [100].”
BackgroundXu, J., Van Dam, N. T., Feng, C., Luo, Y., Ai, H., Gu, R., & Xu, P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.005 · Cited by 212 · cited 1×
“…in cortical regions are related to functional connectivity measures across the brain highlights that SV2A alterations in speci fi c cortical regions could have widespread effects, and potentially lead to mood [126] and anxiety [127] symptoms, negative symptoms [128], and cognitive impairments [129].”
BackgroundVesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry
Wimalasena, K. (2011) · Medicinal Research Reviews · doi:10.1002/med.20187 · Cited by 199 · cited 1×
“Synaptic vesicles are complex structures, containing protein machinery for packaging vesicles with neurotransmitter [14], responding to calcium in fl ux into the presynaptic terminal to initiate exocytosis, mediated by synaptotagmin, a calcium sensor [15], and for fusing with the synaptic terminal…”
BackgroundBarrick, T. R., Charlton, R. A., Clark, C. A., & Markus, H. S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.033 · Cited by 192
Mecca, A. P., O'Dell, R. S., Sharp, E. S., Banks, E. R., Bartlett, H. H., Zhao, W., Lipior, S., Diepenbrock, N. G., Chen, M., Naganawa, M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12582 · Cited by 186 · cited 3×
“The relationship between SV2A PET measures and GM volume (GMV) measured using MRI was reported in nine studies [55, 58, 63, 68, 77, 83, 88, 103, 104].”
BackgroundMethodResultAnti‐tau antibody reduces insoluble tau and decreases brain atrophy
Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185 · cited 1×
“In tauopathies, illnesses strongly associated with brain atrophy [105], lower GMV was anatomically less extensive than lower SV2A tracer uptake [77, 90] and showed smaller effect sizes in group comparisons [87], suggesting that SV2A changes may precede detectable GM atrophy in neurode-generation.”
ResultDendritic spine alterations in schizophrenia
Moyer, C. E., Shelton, M. A., & Sweet, R. A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.11.042 · Cited by 184 · cited 1×
“…however, that while disorders may show involvement of the same brain regions, the mechanisms behind altered SV2A may differ between illnesses, and could preferentially affect synapses in speci fi c cortical layers, as may be the case in schizophrenia [123], or of a certain neurotransmitter class.”
BackgroundSynaptic Changes in Parkinson Disease Assessed with in vivo Imaging
Matuskey, D., Tinaz, S., Wilcox, K. C., Naganawa, M., Toyonaga, T., Dias, M., Henry, S., Pittman, B., Ropchan, J., Nabulsi, N., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25682 · Cited by 180 · cited 4×
“The substantia nigra, a key nucleus in the pathophysiology of PD, showed signi fi cantly lower tracer uptake in three studies [93, 97, 98], while Wilson et al. [95] found changes in the dorsal raphe nuclei and the brainstem.”
BackgroundResultInfluentialWhite matter lesions and depression: A systematic review and meta-analysis
Wang, L., Leonards, C. O., Sterzer, P., & Ebinger, M. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.05.005 · Cited by 177
Synapses: The Brain’s Energy-Demanding Sites
Faria‐Pereira, A., & Morais, V. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073627 · Cited by 169 · cited 1×
“This is expected, considering synapses are responsible for 43 – 55% of brain adenosine triphosphate (ATP) use [117, 118].”
BackgroundHuman temporal lobe potentials in verbal learning and memory processes
Elger, C. E., Grunwald, T., Lehnertz, K., Kutas, M., Helmstaedter, C., Brockhaus, A., Van Roost, D., & Heinze, H. J. (1997) · Neuropsychologia · doi:10.1016/s0028-3932(96)00110-8 · Cited by 166
Age-Related Changes in Axonal and Mitochondrial Ultrastructure and Function in White Matter
Stahon, K. E., Bastian, C., Griffith, S., Kidd, G. J., Brunet, S., & Baltan, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-16.2016 · Cited by 152 · cited 1×
“Mitochondrial SV2A may also explain the speci fi c binding in the CSO: WM does contain mitochondria [147].”
BackgroundSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138 · cited 1×
“Visualisation of the distribution of synaptophysin and SV2A shows that the two proteins colocalise in the synapse, at least in mouse brain, suggesting alignment between the primary targets measured with in vitro and in vivo methods respectively [20].”
BackgroundNaganawa, M., Li, S., Nabulsi, N., Henry, S., Zheng, M.-Q., Pracitto, R., Cai, Z., Gao, H., Kapinos, M., Labaree, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249144 · Cited by 138 · cited 5×
“They have since been used in human research [32, 33], with [ 18 F]SynVesT-1 showing higher BP ND compared to [ 11 C]UCB-J and very rapid kinetics [10, 34, 35].”
BackgroundMethodInfluentialNeuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes
Howes, O., Cummings, C., Chapman, G., & Shatalina, E. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01426-x · Cited by 131 · cited 1×
“This could suggest that the GMV signal is less closely related to the pathophysiological process underlying symptoms than SV2A measures [106].”
BackgroundSelf-citationAssessment of a white matter reference region for 11 C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879230 · Cited by 126
In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography
Bastin, C., Bahri, M. A., Meyer, F., Manard, M., Delhaye, E., Plenevaux, A., Becker, G., Seret, A., Mella, C., Giacomelli, F., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04461-x · Cited by 123 · cited 1×
“Studies also report changes in the amygdala [76, 77], the parahippocampus [76, 78], and the thalamus [74, 78, 81] (Table 5).”
BackgroundSynaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123 · cited 3×
“These aspects have not been comprehensively covered by previous reviews of SV2A imaging [8 – 10] to our knowledge.”
BackgroundMcCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 120 · cited 5×
“…major advantages of BP ND include its versatility, as it can be calculated both using an AIF from V T estimates, providing an outcome measure equalling DVR-1 [7], or using a simpli fi ed reference tissue model (SRTM) which is used to estimate the input function from the reference without ABS [161].”
BackgroundMethodInfluentialSelf-citationAge-changes of brain synapses and synaptic plasticity in response to an enriched environment
Nakamura, H., Kobayashi, S., Ohashi, Y., & Ando, S. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990501)56:3<307::aid-jnr10>3.0.co;2-3 · Cited by 119 · cited 1×
“Indeed, reduced synaptic density secondary to isolation and reduced environmental richness has been detected in animal models [124], which has measurable effects on cognition [125].”
BackgroundSynaptic alterations in the rTg4510 mouse model of tauopathy
Kopeikina, K. J., Polydoro, M., Tai, H., Yaeger, E., Carlson, G. A., Pitstick, R., Hyman, B. T., & Spires‐Jones, T. L. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23234 · Cited by 118 · cited 2×
“This may re fl ect a degree of compensatory upregulation of synapses early in the disorder, which has been reported in mouse models of mutant tau overexpression [112].”
BackgroundResultKoole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118 · cited 1×
“While SUVR values at 60 – 90 min correlate well with DVR measures [55, 143], these studies have been performed in healthy volunteers.”
BackgroundPortals to frailty? Data-driven analyses detect early frailty profiles
Bohn, L., Zheng, Y., McFall, G. P., & Dixon, R. A. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00736-w · Cited by 114
Puzzling Out Synaptic Vesicle 2 Family Members Functions
Bartholome, O., Van den Ackerveken, P., Sánchez Gil, J., de la Brassinne Bonardeaux, O., Leprince, P., Franzen, R., & Rogister, B. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00148 · Cited by 107 · cited 1×
“Other members of the SV2 family could be potential targets for the development of novel PET tracers, as expression of these proteins may be limited to subsets of GABAergic or glutamatergic synapses [150].”
BackgroundRayner, G., Jackson, G., & Wilson, S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.022 · Cited by 104 · cited 1×
“…in cortical regions are related to functional connectivity measures across the brain highlights that SV2A alterations in speci fi c cortical regions could have widespread effects, and potentially lead to mood [126] and anxiety [127] symptoms, negative symptoms [128], and cognitive impairments [129].”
BackgroundO’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 104 · cited 1×
“Two studies, in AD [84] and PSP/CBD [90] respectively, reported that at the individual level, lower tau correlates with higher SV2A, but this relationship becomes negative with higher cortical tau, explaining the positive correlation detected by Holland et al. [85].”
ResultImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104 · cited 2×
“These aspects have not been comprehensively covered by previous reviews of SV2A imaging [8 – 10] to our knowledge.”
BackgroundMethodIn vivo tau pathology is associated with synaptic loss and altered synaptic function
Coomans, E. M., Schoonhoven, D. N., Tuncel, H., Verfaillie, S. C. J., Wolters, E. E., Boellaard, R., Ossenkoppele, R., den Braber, A., Scheper, W., Schober, P., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00772-0 · Cited by 100 · cited 4×
“Five studies [79, 80, 85, 110, 111] compared SV2A and tau accumulation, measured with the PET tracers [ 18 F] fl ortaucipir or [ 18 F]AV-1451.”
BackgroundMethodInfluentialIn vivo evidence of lower synaptic vesicle density in schizophrenia
Radhakrishnan, R., Skosnik, P. D., Ranganathan, M., Naganawa, M., Toyonaga, T., Finnema, S., Hillmer, A. T., Esterlis, I., Huang, Y., Nabulsi, N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01184-0 · Cited by 100 · cited 7×
“The two studies in patients with chronic illness, using V T [55] and BP ND , derived from V T estimates [58] respectively, both showed lower [ 11 C]UCB-J uptake in the cortex and hippocampus, with similar effect sizes.”
BackgroundMethodResultInfluentialSalinas, C. A., Searle, G. E., & Gunn, R. N. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.202 · Cited by 99 · cited 5×
“…underestimate uptake compared to DVR [28], and relies on several assumptions which can bias BP ND results in either direction while misleadingly retaining a good fi t for the model if not met [59]. on SV2A PET outcomes, it seems unlikely that antipsychotic treatment is having a major effect on them.”
BackgroundMethodInfluentialLoss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease
Delva, A., Van Weehaeghe, D., Koole, M., Van Laere, K., & Vandenberghe, W. (2020) · Movement Disorders · doi:10.1002/mds.28216 · Cited by 97
Synaptic Loss in Primary Tauopathies Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Holland, N., Jones, P. S., Savulich, G., Wiggins, J. K., Hong, Y. T., Fryer, T. D., Manavaki, R., Sephton, S. M., Boros, I., Malpetti, M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28188 · Cited by 93 · cited 2×
“This was found in in striatal [90] regions and global GM [86] in PSP/CBD, and cortical regions in bvFTD [89] (Table 7).”
BackgroundCarunchio, I., Pieri, M., Ciotti, M. T., Albo, F., & Zona, C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.00973.x · Cited by 89 · cited 1×
“While it shows negligible binding at the SV2 isoforms SV2B and SV2C [22], it has also been shown to bind to N-type voltage gated calcium channels [40] and AMPA receptors [41], although its af fi nity at these sites has not been reported.”
BackgroundIn vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Sunaert, S., Lemmens, R., Triau, E., Emsell, L., Vandenbulcke, M., & Van Laere, K. (2020) · Neurology · doi:10.1212/wnl.0000000000009818 · Cited by 88 · cited 4×
“In individuals with mild cognitive impairment (MCI) lower [ 11 C]- UCB-J SUVR was found in medial temporal lobe and hippocampus relative to controls [80].”
BackgroundMethodInfluentialRoss, C. A., & Margolis, R. L. (2019) · Complex Psychiatry · doi:10.1159/000501797 · Cited by 86 · cited 1×
“…datasets to investigate correlations of symptoms across disorders with SV2A imaging measures may be useful to investigate the role of synaptic mechanisms in the expression of symptoms across neuropsychiatric illness [151] and the contribution of social factors to imaging biomarkers and symptoms.”
BackgroundEvaluation of18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain
Warnock, G. I., Aerts, J., Bahri, M. A., Bretin, F., Lemaire, C., Giacomelli, F., Mievis, F., Mestdagh, N., Buchanan, T., Valade, A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.136143 · Cited by 85 · cited 1×
“In vitro screening of both [ 11 C]UCB-J and [ 18 F]UCB-H revealed no signi fi cant activity (<50% inhibition at 10 μ M) at a standard panel of receptors, ion channels and enzymes, including >55 potential targets [27, 43].”
Mansur, A., Rabiner, E. A., Comley, R. A., Lewis, Y., Middleton, L. T., Huiban, M., Passchier, J., Tsukada, H., & Gunn, R. N. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.228080 · Cited by 84 · cited 1×
“Studies using V T as an outcome consistently show lower cortical tracer uptake correlating with increasing age, particularly in the caudate nucleus [50, 51] and prefrontal cortex (PFC) [52].”
MethodReduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
Andersen, K. B., Hansen, A. K., Damholdt, M. F., Horsager, J., Skjærbæk, C., Gottrup, H., Klit, H., Schacht, A. C., Danielsen, E. H., Brooks, D. J., et al. (2021) · Movement Disorders · doi:10.1002/mds.28617 · Cited by 84 · cited 4×
“The substantia nigra, a key nucleus in the pathophysiology of PD, showed signi fi cantly lower tracer uptake in three studies [93, 97, 98], while Wilson et al. [95] found changes in the dorsal raphe nuclei and the brainstem.”
BackgroundResultInfluentialMitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease
Wilson, H., Pagano, G., de Natale, E. R., Mansur, A., Caminiti, S. P., Polychronis, S., Middleton, L. T., Price, G., Schmidt, K. F., Gunn, R. N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28064 · Cited by 80 · cited 4×
“The substantia nigra, a key nucleus in the pathophysiology of PD, showed signi fi cantly lower tracer uptake in three studies [93, 97, 98], while Wilson et al. [95] found changes in the dorsal raphe nuclei and the brainstem.”
BackgroundResultInfluentialToyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79 · cited 1×
“For example, signi fi cant reductions in [ 11 C]UCB-J [44] and [ 18 F]SDM-16 [45] SUVR were detected in the hippocampus of the APP/PS1 mouse model of Alzheimer ’ s dementia (AD), in which an independent ultramicroscopy study showed signi fi cant hippocampal synaptic degeneration [46].”
BackgroundComparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study
Chen, M.-K., Mecca, A. P., Naganawa, M., Gallezot, J.-D., Toyonaga, T., Mondal, J., Finnema, S. J., Lin, S.-F., O’Dell, R. S., McDonald, J. W., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211004312 · Cited by 79 · cited 3×
“Three studies have investigated correlations between between FDG and SV2A PET measures, fi nding signi fi cant positive correlations between the measures in AD [76], HD [101] and temporal lobe epilepsy [116] (Table 6).”
BackgroundImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78 · cited 1×
“In a separate study investigating treatment effects, Holmes et al. found that participants with low V T showed signi fi cant increases in [ 11 C]UCB-J V T following ketamine in the dlPFC and ACC ( Table 4), which correlated with a greater reduction in depressive symptoms [66].”
Finnema, S. J., Toyonaga, T., Detyniecki, K., Chen, M., Dias, M., Wang, Q., Lin, S., Naganawa, M., Gallezot, J., Lu, Y., et al. (2020) · Epilepsia · doi:10.1111/epi.16653 · Cited by 78 · cited 2×
“Finnema [116] Asymmetry in BP ND in TLE vs HC Amg (7% ( ± 6%), 3% ( ± 5%)), EC (3% ( ± 14%), 9% ( ± 6)), Fusiform (1% ( ± 6%), 8% ( ± 4)), Hip (17% ( ± 5%), 0% ( ± 4)), Ins (2% ( ± 4%), 10% ( ± 4)), ParaHip (0% ( ± 5%), 9% ( ± 6)), TC (1% ( ± 5%), 9% ( ± 4)), Thal (4% ( ± 6%), − 1% ( ± 2)) If both…”
BackgroundAltered Synapse Stability in the Early Stages of Tauopathy
Jackson, J. S., Witton, J., Johnson, J. D., Ahmed, Z., Ward, M., Randall, A. D., Hutton, M. L., Isaac, J. T., O’Neill, M. J., & Ashby, M. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.013 · Cited by 73
[11C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A
Estrada, S., Lubberink, M., Thibblin, A., Sprycha, M., Buchanan, T., Mestdagh, N., Kenda, B., Mercier, J., Provins, L., Gillard, M., et al. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.03.004 · Cited by 71
Synaptic dysfunction in complex psychiatric disorders: from genetics to mechanisms
Wang, X., Christian, K. M., Song, H., & Ming, G.-L. (2018) · Genome Medicine · doi:10.1186/s13073-018-0518-5 · Cited by 71 · cited 1×
“Unsurprisingly, therefore, synaptic alterations are implicated in many neurological and psychiatric disorders [2, 3].”
BackgroundMercier, J., Archen, L., Bollu, V., Carré, S., Evrard, Y., Jnoff, E., Kenda, B., Lallemand, B., Michel, P., Montel, F., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300482 · Cited by 68 · cited 1×
“Three other tracers with more rapid brain penetrance have been developed: [ 11 C]UCB-A, [ 18 F]UCB-H, and [ 11 C]UCB-J [24].”
MethodImaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67 · cited 6×
“Five studies [79, 80, 85, 110, 111] compared SV2A and tau accumulation, measured with the PET tracers [ 18 F] fl ortaucipir or [ 18 F]AV-1451.”
BackgroundMethodInfluentialSelf-citationSynaptophysin‐dependent synaptobrevin‐2 trafficking at the presynapse‐Mechanism and function
Cousin, M. A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15499 · Cited by 63 · cited 1×
“1B) [8, 17].”
Zhang, J., Wang, J., Xu, X., You, Z., Huang, Q., Huang, Y., Guo, Q., Guan, Y., Zhao, J., Liu, J., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231153730 · Cited by 62 · cited 4×
“…outcome measure, it is dif fi cult to assess whether different analysis methods may explain heterogeneity in the fi ndings across regions or if it could relate to clinical differences, however it is notable that the two which used SUVR both found lower tracer uptake in the Zhang [82] AD vs HC (SUVR)”
BackgroundResultInfluentialMeasuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61 · cited 1×
“8 [ 152 ] , 9 [ 153 ] 1 [ 30 ] 10 m i n s [ 155 ] ( N H P ) 2015 [ 156 ] 10 % [ 155 ] ( N H P ) 2 .”
Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05149-3 · Cited by 61 · cited 2×
“6 [ 30 ] 5 – 20 m i n s [ 35 ] 2021 [ 35 ] 9 % [ 34 ] [ 18 F ] S y nV e s t - 2 9 .”
MethodMecca, A. P., Chen, M.-K., O'Dell, R. S., Naganawa, M., Toyonaga, T., Godek, T. A., Harris, J. E., Bartlett, H. H., Zhao, W., Banks, E. R., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.11.004 · Cited by 61 · cited 2×
“Five studies [79, 80, 85, 110, 111] compared SV2A and tau accumulation, measured with the PET tracers [ 18 F] fl ortaucipir or [ 18 F]AV-1451.”
BackgroundMethodA Mitochondrial Role of SV2a Protein in Aging and Alzheimer’s Disease: Studies with Levetiracetam
Stockburger, C., Miano, D., Baeumlisberger, M., Pallas, T., Arrey, T. N., Karas, M., Friedland, K., & Müller, W. E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150687 · Cited by 60 · cited 1×
“Stockburger et al. [145] identi fi ed SV2A protein in isolated mitochondria in mice, including from outside the synapse, and found that SV2A knockdown altered mitochondrial morphology.”
BackgroundSynaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study
Michiels, L., Delva, A., van Aalst, J., Ceccarini, J., Vandenberghe, W., Vandenbulcke, M., Koole, M., Lemmens, R., & Laere, K. V. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117877 · Cited by 59 · cited 1×
“As Table 3 shows, fi ndings are less clear cut where SUVR is the outcome, with smaller [53] or non-signi fi cant [54] effects, although studies generally show lower values in older age.”
ResultRadiosynthesis of 11C-Levetiracetam: A Potential Marker for PET Imaging of SV2A Expression
Cai, H., Mangner, T. J., Muzik, O., Wang, M.-W., Chugani, D. C., & Chugani, H. T. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500285t · Cited by 58 · cited 1×
“Most such studies use levetiracetam, which has a moderate af fi nity for human SV2A (K i : 6.1 – 8 μ M) [38, 39].”
BackgroundInfluentialBretin, F., Bahri, M. A., Bernard, C., Warnock, G., Aerts, J. J., Mestdagh, N., Buchanan, T. J., Otoul, C., Koestler, F., Miévis, F., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0820-6 · Cited by 56
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder
D’Souza, D. C., Radhakrishnan, R., Naganawa, M., Ganesh, S., Nabulsi, N., Najafzadeh, S., Ropchan, J., Ranganathan, M., Cortes-Briones, J., Huang, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00891-4 · Cited by 55 · cited 3×
“Other regions showed lower tracer uptake in only one study: the PFC in cocaine use [68], the hippocampus in cannabis use [69], and the putamen in gaming disorder [70].”
BackgroundMethodOnwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55 · cited 1×
“Onwordi et al. ’ s study in schizophrenia [108] investigated correlations between SV2A and regional glutamate concentrations as measured by proton magnetic resonance spectroscopy (MRS).”
MethodSelf-citationValidation and noninvasive kinetic modeling of [ 11 C]UCB-J PET imaging in mice
Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, Š., Wyffels, L., Stroobants, S., Mrzljak, L., Dominguez, C., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19864081 · Cited by 54
Synaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53 · cited 3×
“…mood disorders [67, 130], schizophrenia [57, 58], addictions [69, 70], AD [74, 77 – 82, 103 ], amyloid-negative amyloid-negative tauopathies [ 86, 89 – 91 ], LBD [ 98 ] and HD [ 101 ]; this HD study was the only one Studies in this review estimated either SUVR, BP ND , DVR or V T , advantages…”
BackgroundMethodRichter-Landsberg, C., & Gorath, M. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990501)56:3<259::aid-jnr5>3.0.co;2-n · Cited by 52
Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1
Gunn, R. N., Murthy, V., Catafau, A. M., Searle, G. E., Bullich, S., Slifstein, M., Ouellet, D., Zamuner, S., Herance, J. R., Salinas, C. A., et al. (2011) · Synapse · doi:10.1002/syn.20966 · Cited by 52 · cited 1×
“Rather, BPND with the SRTM should be chosen if ABS is unavailable, ideally with explicit modelling of the CSO as a pseudoreference region [144].”
MethodThe glutamatergic synapse: a complex machinery for information processing
Maio, V. D. (2021) · Cognitive Neurodynamics · doi:10.1007/s11571-021-09679-w · Cited by 52 · cited 1×
“Consequently, the synapse is the core unit of information processing in the brain [13].”
BackgroundWang, H., Xu, X., Xu, X., Gao, J., & Zhang, T. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03102-2 · Cited by 51 · cited 1×
“Indeed, reduced synaptic density secondary to isolation and reduced environmental richness has been detected in animal models [124], which has measurable effects on cognition [125].”
BackgroundSynaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study
Delva, A., Michiels, L., Koole, M., Van Laere, K., & Vandenberghe, W. (2022) · Neurology · doi:10.1212/wnl.0000000000012969 · Cited by 51 · cited 4×
“Three studies have investigated correlations between between FDG and SV2A PET measures, fi nding signi fi cant positive correlations between the measures in AD [76], HD [101] and temporal lobe epilepsy [116] (Table 6).”
BackgroundResultInfluentialVanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47 · cited 3×
“Five studies [79, 80, 85, 110, 111] compared SV2A and tau accumulation, measured with the PET tracers [ 18 F] fl ortaucipir or [ 18 F]AV-1451.”
BackgroundMethodKinetics and 28-day test–retest repeatability and reproducibility of [ 11 C]UCB-J PET brain imaging
Tuncel, H., Boellaard, R., Coomans, E. M., de Vries, E. F., Glaudemans, A. W., Feltes, P. K., García, D. V., Verfaillie, S. C., Wolters, E. E., Sweeney, S. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20964248 · Cited by 45 · cited 3×
“However, one study conducted [ 11 C]UCB-J PET scans performed four weeks apart [28] showing comparable low variability to shorter-term studies in three outcome measures, with volume of distribution, distribution volume ratio and nondisplaceable binding potential in total grey matter (GM) showing…”
BackgroundResultSanchez-Varo, R. M., Sánchez‐Mejías, E., Fernandez-Valenzuela, J. J., Castro, V. D., Mejias‐Ortega, M., Gómez-Arboledas, Á., Jiménez, S., Sanchez-Mico, M. V., Trujillo‐Estrada, L., Moreno‐González, I., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.752594 · Cited by 44 · cited 1×
“For example, signi fi cant reductions in [ 11 C]UCB-J [44] and [ 18 F]SDM-16 [45] SUVR were detected in the hippocampus of the APP/PS1 mouse model of Alzheimer ’ s dementia (AD), in which an independent ultramicroscopy study showed signi fi cant hippocampal synaptic degeneration [46].”
BackgroundSmart, K., Liu, H., Matuskey, D., Chen, M.-K., Torres, K., Nabulsi, N., Labaree, D., Ropchan, J., Hillmer, A. T., Huang, Y., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20946198 · Cited by 42 · cited 1×
“To investigate this, Smart et al. [49] studied [ 11 C]UCB-J V T and BP ND in 7 healthy volunteers during visual stimulation, fi nding that, while in fl ux of the tracer to visual cortex correlated with the functional magnetic resonance imaging (fMRI) blood oxygen-level dependent (BOLD) response,…”
MethodMolecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study
Holland, N., Malpetti, M., Rittman, T., Mak, E. E., Passamonti, L., Kaalund, S. S., Hezemans, F. H., Jones, P. S., Savulich, G., Hong, Y. T., et al. (2022) · Brain · doi:10.1093/brain/awab282 · Cited by 39 · cited 4×
“Five studies [79, 80, 85, 110, 111] compared SV2A and tau accumulation, measured with the PET tracers [ 18 F] fl ortaucipir or [ 18 F]AV-1451.”
BackgroundMethodResultInfluentialImaging synaptic density in depression
Holmes, S. E., Abdallah, C., & Esterlis, I. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01368-4 · Cited by 39 · cited 1×
“These covered a range of neuropsychiatric conditions, including mood disorders [67, 130], schizophrenia [57, 58], addictions [69, 70], AD [74, 77 – 82, 103 ], amyloid-negative amyloid-negative tauopathies [ 86, 89 – 91 ], LBD [ 98 ] and HD [ 101 ]; this HD study was the only one Studies in this…”
BackgroundAngarita, G. A., Worhunsky, P. D., Naganawa, M., Toyonaga, T., Nabulsi, N. B., Li, C. R., Esterlis, I., Skosnik, P. D., Radhakrishnan, R., Pittman, B., et al. (2022) · Addiction Biology · doi:10.1111/adb.13123 · Cited by 38 · cited 4×
“Other regions showed lower tracer uptake in only one study: the PFC in cocaine use [68], the hippocampus in cannabis use [69], and the putamen in gaming disorder [70].”
BackgroundMethodInfluentialDoot, R. K., Kurland, B. F., Kinahan, P. E., & Mankoff, D. A. (2011) · Academic Radiology · doi:10.1016/j.acra.2011.10.008 · Cited by 37 · cited 3×
“Indeed, use of quantitative outcome measures which allow for more sophisticated modelling has been shown to increase sensitivity [65].”
BackgroundInfluentialPartial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease
Lu, Y., Toyonaga, T., Naganawa, M., Gallezot, J.-D., Chen, M.-K., Mecca, A. P., van Dyck, C. H., & Carson, R. E. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118248 · Cited by 37
Delva, A., Laere, K. V., & Vandenberghe, W. (2022) · Movement Disorders · doi:10.1002/mds.29148 · Cited by 37 · cited 6×
“While all four found lower [ 11 C]UCB-J BP ND [93], V T [95] or SUVR [97, 98] in the patient group, there were no speci fi c nuclei or cortical areas showing changes in all four studies (Table 5).”
BackgroundResultInfluentialReductions in synaptic marker SV2A in early-course Schizophrenia
Yoon, J. H., Zhang, Z., Mormino, E. C., Davidzon, G., Minzenberg, M., Ballon, J. S., Kalinowski, A., Hardy, K. V., Naganawa, M., Carson, R. E., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.026 · Cited by 37 · cited 4×
“Most SV2A studies using BP ND estimated this via the SRTM [57, 85 – 87, 89 – 91, 104], which rests on assumptions which are violated in SV2A PET (see Schizophrenia section), and which could negatively bias results and potentially overestimate group differences [59].”
BackgroundMethodResultInfluentialIn vivo coupling of dendritic complexity with presynaptic density in primary tauopathies
Mak, E., Holland, N., Jones, P. S., Savulich, G., Low, A., Malpetti, M., Kaalund, S. S., Passamonti, L., Rittman, T., Romero-Garcia, R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.016 · Cited by 36
Zheng, C., Holden, D., Zheng, M.-Q., Pracitto, R., Wilcox, K. C., Lindemann, M., Felchner, Z., Zhang, L., Tong, J., Fowles, K., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05597-5 · Cited by 35 · cited 2×
“A seventh tracer, [ ]UCB-A [31], designed to overcome the metabolic lability of other [ 18 F] tracers.”
BackgroundViviano, M., Barresi, E., Siméon, F. G., Costa, B., Taliani, S., Settimo, F. D., Pike, V. W., & Castellano, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220329204054 · Cited by 35 · cited 1×
“However, even with perfect blocking, residual signal will remain due to nonspeci fi c binding of the tracer, for example to lipids or other macromolecular cellular components [37].”
BackgroundPatel, S., Knight, A. C., Krause, S., Teceno, T. J., Tresse, C., Li, S., Cai, Z., Gouasmat, A., Carroll, V. M., Barret, O., et al. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01428-0 · Cited by 33 · cited 1×
“8 [ 152 ] , 9 [ 153 ] 1 [ 30 ] 10 m i n s [ 155 ] ( N H P ) 2015 [ 156 ] 10 % [ 155 ] ( N H P ) 2 .”
Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia
Wang, X., Chang, Z., & Wang, R. (2023) · Communications Biology · doi:10.1038/s42003-023-04637-0 · Cited by 32 · cited 1×
“…in cortical regions are related to functional connectivity measures across the brain highlights that SV2A alterations in speci fi c cortical regions could have widespread effects, and potentially lead to mood [126] and anxiety [127] symptoms, negative symptoms [128], and cognitive impairments [129].”
BackgroundLower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch, R., Holmes, S. E., Jastreboff, A. M., Potenza, M. N., Baldassarri, S. R., Carson, R. E., Pietrzak, R. H., & Esterlis, I. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01111-5 · Cited by 31 · cited 2×
“This was not found in a similar study by Asch et al. [67], who found no correlations between depressive symptomatology and [ 11 C]UCB-J V T in subjects with obesity and various psychiatric diagnoses.”
BackgroundResultTargeting SV2A for Discovery of Antiepileptic Drugs
Kaminski, R. M., Gillard, M., & Klitgaard, H. (2012) · Jasper's Basic Mechanisms of the Epilepsies · doi:10.1093/med/9780199746545.003.0076 · Cited by 31
Pazarlar, B. A., Aripaka, S. S., Petukhov, V., Pinborg, L. H., Khodosevich, K., & Mikkelsen, J. D. (2022) · Molecular Brain · doi:10.1186/s13041-022-00931-w · Cited by 31 · cited 1×
“Future research directions SV2A is expressed in all synapses so far investigated, including GABAergic [148], glutamatergic [148], and dopaminergic [149] synapses.”
BackgroundVanoye-Carlo, A., & Gómez-Lira, G. (2019) · Brain Research · doi:10.1016/j.brainres.2019.03.021 · Cited by 30 · cited 1×
“Future research directions SV2A is expressed in all synapses so far investigated, including GABAergic [148], glutamatergic [148], and dopaminergic [149] synapses.”
BackgroundAndersen, K. B., Hansen, A. K., Schacht, A. C., Horsager, J., Gottrup, H., Klit, H., Danielsen, E. H., Poston, K. L., Pavese, N., Brooks, D. J., et al. (2023) · Movement Disorders · doi:10.1002/mds.29375 · Cited by 30 · cited 1×
“Four cross-sectional PET studies have been performed in Parkinson ’ s disease (PD) [93 – 96] (Table 5 Supplementary Table 4).”
BackgroundBertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221101648 · Cited by 29
Toyonaga, T., Khattar, N., Wu, Y., Lu, Y., Naganawa, M., Gallezot, J., Matuskey, D., Mecca, A. P., Pittman, B. P., Dias, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06487-8 · Cited by 29 · cited 1×
“Studies using V T as an outcome consistently show lower cortical tracer uptake correlating with increasing age, particularly in the caudate nucleus [50, 51] and prefrontal cortex (PFC) [52].”
Method11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies
Nicastro, N., Holland, N., Savulich, G., Carter, S. F., Mak, E., Hong, Y. T., Milicevic Sephton, S., Fryer, T. D., Aigbirhio, F. I., Rowe, J. B., et al. (2020) · European Journal of Hybrid Imaging · doi:10.1186/s41824-020-00093-9 · Cited by 28 · cited 3×
“The relationship between SV2A PET measures and GM volume (GMV) measured using MRI was reported in nine studies [55, 58, 63, 68, 77, 83, 88, 103, 104].”
BackgroundMethodVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
Andersen, K. B., Hansen, A. K., Knudsen, K., Schacht, A. C., Damholdt, M. F., Brooks, D. J., & Borghammer, P. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.007 · Cited by 27 · cited 1×
“As Table 3 shows, fi ndings are less clear cut where SUVR is the outcome, with smaller [53] or non-signi fi cant [54] effects, although studies generally show lower values in older age.”
ResultEffects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine
Takaki, M., Kodama, M., Mizuki, Y., Kawai, H., Yoshimura, B., Kishimoto, M., Sakamoto, S., Okahisa, Y., & Yamada, N. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.004 · Cited by 26 · cited 1×
“Similar results were found on in vitro measures such as neuroligin puncta density [60] and synapto-physin immunoreactivity [61].”
ResultTang, Y., Liu, P., Li, W., Liu, Z., Zhou, M., Li, J., Yuan, Y., Fang, L., Wang, M., Shen, L. H., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15451 · Cited by 26 · cited 1×
“They have since been used in human research [32, 33], with [ 18 F]SynVesT-1 showing higher BP ND compared to [ 11 C]UCB-J and very rapid kinetics [10, 34, 35].”
MethodHolland, N., Jones, P. S., Savulich, G., Naessens, M., Malpetti, M., Whiteside, D. J., Street, D., Swann, P., Hong, Y. T., Fryer, T. D., et al. (2023) · Movement Disorders · doi:10.1002/mds.29421 · Cited by 26 · cited 3×
“…disorders [67, 130], schizophrenia [57, 58], addictions [69, 70], AD [74, 77 – 82, 103 ], amyloid-negative amyloid-negative tauopathies [ 86, 89 – 91 ], LBD [ 98 ] and HD [ 101 ]; this HD study was the only one Studies in this review estimated either SUVR, BP ND , DVR or V T , advantages and…”
BackgroundMethodLongitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease
Delva, A., Laere, K. V., & Vandenberghe, W. (2023) · Movement Disorders · doi:10.1002/mds.29501 · Cited by 26 · cited 1×
“Two SV2A PET studies have been conducted in Huntington ’ s disease (HD); one cross-sectional [101] and the second its longitudinal extension [102] (Table 5, Supplementary Table 4).”
BackgroundGottschling, C., Geißler, M., Springer, G., Wolf, R. J., Juckel, G., & Faissner, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.08.055 · Cited by 25 · cited 1×
“In contrast, synaptic density, as observed with microscopy, has been found to be higher with olanzapine and lower with haloperidol in a rat study [62].”
ResultAutoradiographic mapping of synaptic vesicle glycoprotein 2A in non‐human primate and human brain
Varnäs, K., Stepanov, V., & Halldin, C. (2020) · Synapse · doi:10.1002/syn.22157 · Cited by 25 · cited 1×
“SV2A is, as far as is known, ubiquitously expressed in synapses, making it a good marker of synapses [19].”
BackgroundRamos‐Miguel, A., Jones, A. A., Petyuk, V., Barakauskas, V., Barr, A. M., Leurgans, S. E., Jager, P. L. D., Casaletto, K. B., Schneider, J. A., Bennett, D. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02282-7 · Cited by 24
In vivo exploration of synaptic projections in frontotemporal dementia
Salmon, E., Bahri, M. A., Plenevaux, A., Becker, G., Seret, A., Delhaye, E., Degueldre, C., Balteau, E., Lemaire, C., Luxen, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95499-1 · Cited by 21 · cited 2×
“The relationship between SV2A PET measures and GM volume (GMV) measured using MRI was reported in nine studies [55, 58, 63, 68, 77, 83, 88, 103, 104].”
BackgroundMethodImaging Synaptic Density: A Different Look at Neurologic Diseases
Rabiner, E. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198317 · Cited by 20 · cited 1×
“The inferior brain uptake of [ 11 C]UCB-A relative to the other UCB tracers [25] meant it has not proceeded to human studies [26].”
BackgroundSynaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography
Chen, Z., Liao, G., Wan, N., He, Z., Chen, D., Tang, Z., Long, Z., Zou, G., Peng, L., Wan, L., et al. (2023) · Movement Disorders · doi:10.1002/mds.29395 · Cited by 19
Whiteside, D. J., Holland, N., Tsvetanov, K. A., Mak, E., Malpetti, M., Savulich, G., Jones, P. S., Naessens, M., Rouse, M. A., Fryer, T. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44307-7 · Cited by 19 · cited 8×
“Two studies, in AD [84] and PSP/CBD [90] respectively, reported that at the individual level, lower tau correlates with higher SV2A, but this relationship becomes negative with higher cortical tau, explaining the positive correlation detected by Holland et al. [85].”
BackgroundMethodResultInfluentialHalff, E. F., Cotel, M.-C., Natesan, S., McQuade, R., Ottley, C. J., Srivastava, D. P., Howes, O. D., & Vernon, A. C. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113203 · Cited by 18 · cited 2×
“However, administration of the antipsychotics haloperidol and olanzapine to rats for 28 days resulted in no difference in SV2A on markers [55, 60] relative to vehicle-treated rats.”
BackgroundResultSelf-citationFang, X. T., Volpi, T., Holmes, S. E., Esterlis, I., Carson, R. E., & Worhunsky, P. D. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1124254 · Cited by 18 · cited 3×
“Studies using V T as an outcome consistently show lower cortical tracer uptake correlating with increasing age, particularly in the caudate nucleus [50, 51] and prefrontal cortex (PFC) [52].”
BackgroundMethodSmart, K. A., Uribe, C., Desmond, K. L., Martin, S. L., Vasdev, N., & Strafella, A. P. (2023) · Molecular Imaging · doi:10.1155/2023/1855985 · Cited by 18 · cited 1×
“They have since been used in human research [32, 33], with [ 18 F]SynVesT-1 showing higher BP ND compared to [ 11 C]UCB-J and very rapid kinetics [10, 34, 35].”
MethodDrake, L. R., Wu, Y., Naganawa, M., Asch, R., Zheng, C., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266470 · Cited by 18
Moallemian, S., Salmon, É., Bahri, M. A., Beliy, N., Delhaye, E., Balteau, E., Degueldre, C., Phillips, C. L. M., & Bastin, C. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.08.001 · Cited by 16
Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain
Cauwenberge, M. G. A. V., Delva, A., Casteele, T. V., Laroy, M., Radwan, A., Vansteelandt, K., den Stock, J. V., Bouckaert, F., Laere, K. V., Emsell, L., et al. (2023) · Movement Disorders · doi:10.1002/mds.29570 · Cited by 16 · cited 1×
“SV2A imaging in PD does therefore show evidence for lower tracer uptake in expected mesencephalic regions, however the anatomical extent and severity of synaptic protein loss shows little relationship with motor symptoms, except in participants with mild [95] or subclinical [99] disease.”
BackgroundQuantifying synaptic number and structure: effects of stain and post-mortem delay
Petit, T. L., & LeBoutillier, J. C. (1990) · Brain Research · doi:10.1016/0006-8993(90)91037-h · Cited by 15 · cited 1×
“However, synaptic changes may occur after death [5], and cause of death may affect synapses [6].”
BackgroundPreclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
Thomsen, M. B., Schacht, A. C., Alstrup, A. K. O., Jacobsen, J., Lillethorup, T. P., Bærentzen, S. L., Noer, O., Orłowski, D., Elfving, B., Müller, H. K., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01506-8 · Cited by 15 · cited 1×
“Only one other similar study has been performed, which examined relationships between SV2A auto-radiography using [ 3 H]UCB-J and synaptophysin mRNA levels, fi nding no correlation [48], however these authors did not look at synaptophysin protein levels.”
Lower synaptic density associated with gaming disorder: an 18 F‐SynVesT‐1 PET imaging study
Hou, J., Xiao, Q., Zhou, M., Xiao, L., Yuan, M., Zhong, N., Long, J., Luo, T., Hu, S., & Dong, H. (2023) · General Psychiatry · doi:10.1136/gpsych-2023-101112 · Cited by 15 · cited 3×
“Other regions showed lower tracer uptake in only one study: the PFC in cocaine use [68], the hippocampus in cannabis use [69], and the putamen in gaming disorder [70].”
BackgroundMethodNavacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 13
Löffler, J., Herrmann, H., Scheidhauer, E., Wirth, M., Wasserloos, A., Solbach, C., Glatting, G., Beer, A. J., Rasche, V., & Winter, G. (2022) · Cancers · doi:10.3390/cancers14163870 · Cited by 12
Pracitto, R., Wilcox, K. C., Lindemann, M., Tong, J., Zheng, C., Li, S., Finnema, S. J., Huang, Y. H., & Cai, Z. (2021) · ACS Omega · doi:10.1021/acsomega.1c02433 · Cited by 6 · cited 2×
“8 [ 152 ] , 9 [ 153 ] 1 [ 30 ] 10 m i n s [ 155 ] ( N H P ) 2015 [ 156 ] 10 % [ 155 ] ( N H P ) 2 .”
Zheng, C., Toyonaga, T., Chen, B., Nicholson, L., Mennie, W., Liu, M., Spurrier, J. M., DeLuca, K., Strittmatter, S. M., Carson, R. E., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1045644 · Cited by 5 · cited 1×
“For example, signi fi cant reductions in [ 11 C]UCB-J [44] and [ 18 F]SDM-16 [45] SUVR were detected in the hippocampus of the APP/PS1 mouse model of Alzheimer ’ s dementia (AD), in which an independent ultramicroscopy study showed signi fi cant hippocampal synaptic degeneration [46].”
BackgroundImaging synaptic microstructure and synaptic loss in vivo in early Alzheimer’s DiseasePreprint
Venkataraman, A. V., Bishop, C., Mansur, A., Rizzo, G., Lewis, Y. L., Kocagöncü, E., Lingford-Hughes, A. R., Huiban, M., Passchier, J., Rowe, J. B., et al. (2021) · medRxiv · doi:10.1101/2021.11.23.21266746 · Cited by 3 · cited 4×
“Two of these studies [81, 90] additionally detected positive correlations in healthy controls.”
BackgroundMethodResultInfluentialCai, Z., Wu, Y., Drake, L. R., Naganawa, M., Najafzadeh, S., Pracitto, R., Lindemann, M., Li, S., Ropchan, J. R., Labaree, D. C., et al. (2021) · Journal of Nuclear Medicine · Cited by 1
Zheng, C., Holden, D., Zheng, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.449978 · Cited by 1
69. Lower Grey Matter Volume is not Related to Synaptic Density in Late Life Depression
Casteele, T. V., Laroy, M., Cauwenberge, M. G. A. V., Koole, M. J. B., Dupont, P. J., Sunaert, S. G., den Stock, J. V., Bouckaert, F., Laere, K. V., Emsell, L., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.02.309 · Cited by 1 · cited 4×
“The relationship between SV2A PET measures and GM volume (GMV) measured using MRI was reported in nine studies [55, 58, 63, 68, 77, 83, 88, 103, 104].”
BackgroundMethodResultInfluential
Research works printed but not linked: 4
- 23. Cai H, Mangner T, Muzik O, Chugani H. Radiosynthesis and preliminary eva- luation of 11C-levetiracetam for PET imaging of SV2A expression. Soc Nuclear Med. 2014; 55:1795.
- 30. Cai Z, Drake L, Naganawa M, Najafzadeh S, Pracitto R, Lindemann M. et al. First- in-human study of [18F] SynVesT-2, a novel SV2A radioligand with fast kinetics and high specific binding signals. Soc Nuclear Med. 2020;61:462 · DOI · Paper page
- 56. Onwordi EC, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, et al. Synaptic Terminal Density Early in the Course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging Study of Synaptic Vesicle Glycoprotein 2A (SV2A). Biol Psychiatry 2023;S0006-3223:01353-7.
- 146. Reichert JS. SV2A-just a synaptic vesicle protein? Unravelling the interaction of SV2A and mitochondria in the pathogenesis and therapy of Morbus Alzheimer. Dissertation, Mainz, Johannes Gutenberg-Universität Mainz, 2022;2022.
Cited by
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders
Boudriot, E., Stephan, M., Rabe, F., Smigielski, L., Schmitt, A., Falkai, P., Ziller, M. J., Rossner, M. J., Homan, P., Papiol, S., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4230 · Cited by 22
Bhujbal, S. P., & Hah, J. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01566-w · Cited by 18
“By comparison, the main limitations of PROTACs in the CNS stem from challenges in brain penetration and dependence on neuronal E3 ligase biology, rather than on-target engagement itself (Bálint et al. 2024).”
InfluentialCopper-mediated radiochemistry: historical impact, current trends, and future possibilities
Bowden, G. D., Müller, M., Herth, M. M., Sanford, M. S., & Scott, P. J. H. (2025) · npj Imaging · doi:10.1038/s44303-025-00087-x · Cited by 18
Vano, L. J., McCutcheon, R. A., Sedlacik, J., Rutigliano, G., Kaar, S. J., Finelli, V., Lobo, M. C., Berry, A., Statton, B. K., Fazlollahi, A., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03195-7 · Cited by 17
“Eligible participants were aged 18 – 45 years, with the upper limit chosen to focus on individuals early in the illness course, given potential progressive brain changes in schizophrenia [29].”
Self-citationGupta, R., Jha, N. K., Kumar, N., Nagraik, R., & Ravi, K. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1762930 · Cited by 16
“Genome-wide association studies (GWAS) have identified numerous susceptibility loci across disorders including SCZ, bipolar disorder, MDD, and ASD.”
Influential
Metadata
- Authors
- Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R.
- Affiliations
- King's College London (GB)
- Corresponding author
- Howes, Oliver
- Venue
- Neuropsychopharmacology
- Published
- 2024-08-12
- Volume
- 50
- Issue
- 1
- Pages
- 164-183
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC11525650
- OpenAlex
- W4401527108
- Cited by
- 34
- References
- 161
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 1
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-03-19)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, cc-by)
- Funders
- RCUK | Medical Research Council (MC_U120097115, MR/W005557/1, MR/V013734/1)
- Wellcome Trust (094849/Z/10/Z)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- synaptic markers, SV2A, mental illness, neurological disorders, tauopathy, Huntington's disease, synucleinopathies, Parkinson's disease, corticobasal degeneration, progressive supranuclear palsy, schizophrenia, depression, post-traumatic stress disorder, addiction, functional connectivity, glucose metabolism, cognitive impairment, transdiagnostic mechanisms, healthy aging
- MeSH terms
- Animals, Mental Disorders, Brain, Humans, Nervous System Diseases, Synapses, Positron-Emission Tomography, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.